Digestive Health & Gastroenterology Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

This Phase 3 trial is exploring a combination treatment of mirikizumab and tirzepatide for adults living with moderately to severely active Crohn's disease who are also obese or overweight. If successful, this approach could help reduce inflammation from Crohn's disease while also addressing challenges related to weight, potentially improving symptoms and overall quality of life. The study is recruiting participants worldwide and will continue for up to 61 weeks.

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

This Phase 3b study tests the combination of mirikizumab and tirzepatide in adults with moderately to severely active ulcerative colitis who are also obese or overweight. Success in this trial may offer a new treatment option that not only eases ulcerative colitis symptoms but also supports significant weight loss. The trial is currently enrolling participants at many sites globally and will last up to 61 weeks.

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

This large Phase 3 trial is testing two drugs, retatrutide and tirzepatide, in adults with metabolic dysfunction-associated steatotic liver disease, a condition linked to serious liver problems. If effective, these treatments could lower the risk of severe complications and improve liver health for many people. The study plans to enroll around 4,500 adults across various countries and will run for approximately four years.

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

This Phase 3 study focuses on children and adolescents with moderate-to-severe ulcerative colitis or Crohn's disease. It is testing mirikizumab as a long-term treatment that may help control these diseases better and enhance quality of life for young patients. The trial is recruiting globally and includes up to 44 visits over about three years.

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

This Phase 3 trial is investigating a new combination of immunotherapy drugs with chemotherapy for people who have advanced upper gastrointestinal tract adenocarcinoma that cannot be surgically removed and has spread. If successful, this treatment might provide an option that improves survival for patients facing this difficult cancer. The study is active with over 1,000 participants worldwide but is not currently recruiting.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.